Mitochondrial Functionalism in HIV-Infected Children Receiving Antiretroviral Therapy

Total Page:16

File Type:pdf, Size:1020Kb

Mitochondrial Functionalism in HIV-Infected Children Receiving Antiretroviral Therapy Mitochondrial functionalism in HIV-infected children receiving antiretroviral therapy Constanza Morén Núñez ADVERTIMENT. La consulta d’aquesta tesi queda condicionada a l’acceptació de les següents condicions d'ús: La difusió d’aquesta tesi per mitjà del servei TDX (www.tdx.cat) ha estat autoritzada pels titulars dels drets de propietat intel·lectual únicament per a usos privats emmarcats en activitats d’investigació i docència. No s’autoritza la seva reproducció amb finalitats de lucre ni la seva difusió i posada a disposició des d’un lloc aliè al servei TDX. No s’autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant al resum de presentació de la tesi com als seus continguts. En la utilització o cita de parts de la tesi és obligat indicar el nom de la persona autora. ADVERTENCIA. La consulta de esta tesis queda condicionada a la aceptación de las siguientes condiciones de uso: La difusión de esta tesis por medio del servicio TDR (www.tdx.cat) ha sido autorizada por los titulares de los derechos de propiedad intelectual únicamente para usos privados enmarcados en actividades de investigación y docencia. No se autoriza su reproducción con finalidades de lucro ni su difusión y puesta a disposición desde un sitio ajeno al servicio TDR. No se autoriza la presentación de su contenido en una ventana o marco ajeno a TDR (framing). Esta reserva de derechos afecta tanto al resumen de presentación de la tesis como a sus contenidos. En la utilización o cita de partes de la tesis es obligado indicar el nombre de la persona autora. WARNING. On having consulted this thesis you’re accepting the following use conditions: Spreading this thesis by the TDX (www.tdx.cat) service has been authorized by the titular of the intellectual property rights only for private uses placed in investigation and teaching activities. Reproduction with lucrative aims is not authorized neither its spreading and availability from a site foreign to the TDX service. Introducing its content in a window or frame foreign to the TDX service is not authorized (framing). This rights affect to the presentation summary of the thesis as well as to its contents. In the using or citation of parts of the thesis it’s obliged to indicate the name of the author. UNIVERSITAT DE BARCELONA FACULTAT DE MEDICINA MITOCHONDRIAL FUNCTIONALISM IN HIV-INFECTED CHILDREN RECEIVING ANTIRETROVIRAL THERAPY Memòria de Tesi per a optar al grau de Doctora per la Universitat de Barcelona Presentada per: Constanza Morén Núñez Co-dirigida per: Doctor Òscar Miró i Andreu Doctora Clàudia Fortuny Guasch Mitochondrial Functionalism Laboratory. Internal Medicine Department, IDIBAPS, University of Barcelona Hospital Clínic of Barcelona Facultat de Medicina Departament de Medicina C/Casanova 143, 08036 Barcelona Tel. 93 227 5400 Ext 2907 Fax 93 227 9365 Òscar Miró i Andreu, adjunt de plantilla de la Unitat d'Urgències del Hospital Clínic de Barcelona. Certifica: Que Constanza MORÉN NÚÑEZ ha treballat sota la meva Co-Direcció, la Tesi Doctoral sobre el tema: “MITOCHONDRIAL FUNCTIONALISM IN HIV-INFECTED CHILDREN RECEIVING ANTIRETROVIRAL THERAPY ”, que està en condicions de ser presentada per a l´obtenció del Grau de Doctor. El que certifico a Barcelona a 05 de desembre de 2011. Òscar MIRÓ i ANDREU Facultat de Medicina Prof. R. Jiménez Departament de Pediatria Catedràtic de Pediat Hospital Sant Joan de Déu Passeig de Sant Joan de Déu, 2 08950 Esplugues de Llobregat Tel. 93 253 21 30 Fax 93 280 41 79 E-mail: [email protected] Clàudia FORTUNY GUASCH, Professora Associada de Pediatria de la Facultat de Medicina de la Universitat de Barcelona. Certifica: Que Constanza MORÉN NÚÑEZ ha treballat sota la meva Co-Direcció, la Tesi Doctoral sobre el tema: “MITOCHONDRIAL FUNCTIONALISM IN HIV-INFECTED CHILDREN RECEIVING ANTIRETROVIRAL THERAPY ”, que està en condicions de ser presentada per a l´obtenció del Grau de Doctor. El que certifico a Barcelona a 05 de desembre de 2011. Clàudia FORTUNY GUASCH No es valiente el que no tiene miedo, sino el que sabe conquistarlo. Nelson Mandela A la Ita A mi madre A mi padre Agraïments Tinc la sensació que aquesta serà l’escriptura més difícil de tota la Tesi, no perquè no sàpiga què agrair a qui sino, perquè hi ha massa a agrair a molta gent que m’ha acompanyat en aquesta aventura que ha durat gairebé cinc anys. De tot, el més difícil será que pugui plasmar en forma de paraules, que pugui arribar a cadascun de vosaltres, el meu més sincer agraïment amb tota la intensitat que sento. A mi madre, por estar ahí siempre, por haberme ayudado a crecer y ser una referencia para todo. A mi padre, por regalarnos su confianza, por ser un ser admirable y valiente, de quien todos debemos tomar ejemplo. Y a los dos, porque sin vosotros nada hubiera sido posible en mi vida, ni la propia vida. A mis hermanas, Patricia y Beatriz, por crecer conmigo, por ser dos faros que iluminan mi vida desde el primer día. Si dejaran elegir a los hermanos os hubiera elegido a vosotras exactamente como sois. A Pedro y Jari, por su lado divertido, por llenar y completar nuestras vidas. A mis sobrinas Sonia, Tania y Paola, ya no concebimos la vida sin vosotras. A mi amor Javi, a quien quiero muchísimo, con quien me encanta compartir cada día. Gracias por compartir cada día conmigo también. Por enseñarme todo tipo de cosas, desde las más mundanas, como jugar a fútbol, Backgamon, Rummy cub, o llevar una moto, hasta las más importantes como extraer el jugo y disfrutar del mejor lado de la vida, en definitiva, por hacerme tan feliz. A toda mi familia. A mis tíos, Javi y especialmente Maite por cuidarme cuando fue necesario. También a mis tías Isabel y Pili por su generosidad y por encargarse de reunirnos siempre, por su interés en mis trabajos. A mis primos y primitos más pequeños, y especialmente a Silvia, por su arte, su personalidad y por la tapa de esta Tesis. Y a la Ita, por estar siempre ahí pase lo que pase, enseñando tantas cosas. Moltíssimes gràcies als meus dos directors de Tesi: el Dr. Òscar Miró i Andreu de la Unitat d’Urgències de l’Hospital Clínic i la Dra. Clàudia Fortuny de la Unitat de Pediatria de l’Hospital Sant Joan de Déu. Sense vosaltres aquesta Tesi probablement no hagués existit mai. Als companys de la Unitat de Pediatria, del Departament Infeccioses de l’Hospital Sant Joan de Déu: Núria Rovira, Ester Corrales i, molt especialment, al Dr. Antoni Noguera (Ton) per la seva paciència, infinita ajuda i estreta col·laboració, i pels seus ànims constants en forma d’ATP. Moltíssimes gràcies també al Dr. Francesc Cardellach López, de qui és admirable la seva capacitat de treball, de saber estar en tot i arribar a tot. Thanks to Dr. Antoni Barrientos and his group Álex O’Campo, JingJing, Flavia Montanesi, Paula Clemente, Darryll Horn, Ileana Soto and all the colleagues from the Department of Neurology and Biochemistry and Molecular Biology from the University of Miami, for the good welcome, for sharing the great environment of your lab during my stay, for the fruitful collaboration and, of course, for the “Mitopapers of the week”. Gràcies a tots els membres i suplents del Tribunal d’aquesta Tesi per haver accedit a participar: El Dr. Josep Maria Grau del Departament de Medicina Interna de l’Hospital Clínic, el Dr. Antoni Andreu, Director del Programa de Medicina Molecular de Vall d’Hebron, el Dr. Ramon Martí, Investigador del Laboratori de Patologia Mitocondrial de l’Institut de Recerca de Vall d’Hebron, la Dra. Belén Pérez i el Dr. Rafael Artuch, del Departament de Pediatria de l’Hospital Sant Joan de Déu, i la Dra. Eugènia Negredo del Departament de Medicina Interna de l’Hospital Universitari Germans Trias i Pujol. A nuestros colegas Rubén y Mario del laboratorio de Neurología experimental (IDIBAPS- Hospital Clínic), con quien tendremos la suerte de emprender un proyecto de forma inminente, por los desayunos con debates científicos incluídos. A todos los del grupo CIBERER, gestores y administrativos, entre ellos Andrés Medrano, Ana Sáez, Vicente de Juan, Mónica Bescós y Verónica García; así como a nuestros acompañantes de la cadena y de la depleción, incluídos Elena Garcia y Ramiro Martínez de Vall Hebrón, Ana Belén Cortés y Juan Carlos Rodríguez de Sevilla, Miguel Ángel Martín, Aitor Delmiró y Alberto Blázquez, del Hospital XXII de Octubre de Madrid, Ester López de la Universidad de Zaragoza, Belén Bornstein y Rosana Hernández de la Universidad Autónoma de Madrid, Núria Bujan, Aleix Navarro y Paz Briones del Institut de Bioquímica Clínica de la Maternitat. Por supuesto, a todos esos amigos tan geniales, que hacen que la vida sea más divertida y una Tesis más llevadera. A Isabel, por sus buenos consejos. A Eva, Santi i Anna, Janín. A los de Tarragona, Yolanda, Viso, Yolandeta, Josep Maria, Elena, Berto, Sandra, Pasqu, Kitus i Ana. Als del Delta, Núria, Maria i Enric. A los de la UAB, Sandra, Juani, Helena, Núria, Eliz, Xabi, Isaac y Álex. A aquellos con quien tuve la suerte de convivir, Judit, Sadhbh, Koldo. A la meva amiga Marta, a qui per lluny que estigui sento sempre molt a prop. A les de Cerdanyola, Raquel, Anna i Roser. A tota la “Irish family”, Roser, Laia, Jaume, Cris, Noèlia, Laura i Marta. I gràcies a l’Aura i a l’Alberto pel disseny gràfic. A totes les companyes de futbol, esport complexe però ben necessari en l’etapa final d’una Tesi. A todos los amigos de Javi, por la buena energía que desprenden siempre: Ferran, Anna y Francesc, Thomas, Lucía y Pedro, Raúl, Manel i Mercè, Sandra, Miguel y Estefanía, Cesc, Hanna y Joan, Marc, Pablo y Lara, Álex y Ester.
Recommended publications
  • Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS Or Death
    Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death Casadellà, Maria; Cozzi-Lepri, Alessandro; Phillips, Andrew; Noguera-Julian, Marc; Bickel, Markus; Sedlacek, Dalibor; Zilmer, Kai; Clotet, Bonaventura; Lundgren, Jens D; Paredes, Roger; EuroSIDA in EuroCoord Published in: PloS one DOI: 10.1371/journal.pone.0166613 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Casadellà, M., Cozzi-Lepri, A., Phillips, A., Noguera-Julian, M., Bickel, M., Sedlacek, D., Zilmer, K., Clotet, B., Lundgren, J. D., Paredes, R., & EuroSIDA in EuroCoord (2017). Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death. PloS one, 12(1), [e0166613]. https://doi.org/10.1371/journal.pone.0166613 Download date: 28. Sep. 2021 RESEARCH ARTICLE Plasma HIV-1 Tropism and the Risk of Short- Term Clinical Progression to AIDS or Death Maria Casadellà1,2*, Alessandro Cozzi-Lepri3, Andrew Phillips3, Marc Noguera-Julian1,2,4, Markus Bickel5, Dalibor Sedlacek6, Kai Zilmer7, Bonaventura Clotet1,2,4,8, Jens D. Lundgren9, Roger Paredes1,2,4,8, EuroSIDA in EuroCOORD¶ 1 IrsiCaixa AIDS Research Institute, Badalona, Catalonia, Spain, 2 Universitat Autònoma de Barcelona, Catalonia, Spain, 3 Royal Free Hospital, London, United Kingdom, 4 Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia, Spain, 5 Goethe University, Frankfurt/Main, Germany, 6 Charles University a1111111111 Hospital, Plzen, Česka Republika, 7 West-Tallinn Central Hospital, Tallinn, Estonia, 8 HIV Unit, Hospital a1111111111 Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, 9 CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark a1111111111 a1111111111 ¶ Membership of this author group is listed in the Acknowledgments.
    [Show full text]
  • Analysis of Variations in Susceptibility and Transcriptome Responses in Tomato to Two-Spotted Spider Mite Feeding
    Western University Scholarship@Western Digitized Theses Digitized Special Collections 2011 ANALYSIS OF VARIATIONS IN SUSCEPTIBILITY AND TRANSCRIPTOME RESPONSES IN TOMATO TO TWO-SPOTTED SPIDER MITE FEEDING Ingrid Fung Follow this and additional works at: https://ir.lib.uwo.ca/digitizedtheses Recommended Citation Fung, Ingrid, "ANALYSIS OF VARIATIONS IN SUSCEPTIBILITY AND TRANSCRIPTOME RESPONSES IN TOMATO TO TWO-SPOTTED SPIDER MITE FEEDING" (2011). Digitized Theses. 3258. https://ir.lib.uwo.ca/digitizedtheses/3258 This Thesis is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western. It has been accepted for inclusion in Digitized Theses by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. ANALYSIS OF VARIATIONS IN SUSCEPTIBILITY AND TRANSCRIPTOME RESPONSES IN TOMATO TO TWO-SPOTTED SPIDER MITE FEEDING SPINE TITLE Analysis of Tomato-Spider mite Interactions THESIS FORMAT Monograph BY Ingrid Fung Graduate Program in Biology A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science The School of Graduate and Postdoctoral Studies The University of Western Ontario London, Ontario, Canada © Ingrid Fung 2011 THE UNIVERSITY OF WESTERN ONTARIO SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES CERTIFICATE OF EXAMINATION Supervisor Examiners Dr. Vojislava Grbic Dr. Mark Gijzen Supervisory Committee Dr. Denis Maxwell Dr. Susanne Kohalmi Dr. Shiva Singh Dr. Priti Krishna The thesis by Ingrid Fung entitled: Analysis of Variation in Susceptibility and Transcriptome Responses of Tomato to Two-Spotted Spider Mite Feeding is accepted in partial fulfilment of the requirements for the degree of Master of Science Date Chair of the Thesis Examination Board ABSTRACT The two-spotted spider mite (Tetranychus urticae Koch) is a pest of tomatoes (Solarium lycopersicum) worldwide.
    [Show full text]
  • Correlating HIV Tropism with Immunological Response Under Cart
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`0::$%& 01& 2."N.& (D"I:& N5%:5%*& A0*($& W*"W%*:0%1& 1I45& (1& 4%$$& :*"W01L& 4"I$)& W$(F& (& *"$%& 9"*& 1I45& 0.4"LW$%:%& 0LLI.%& *%1W".1%Y& K5I1& :501& 1:I)F& N(1&
    [Show full text]
  • Coreceptor Tropism Assays
    CORECEPTOR TROPISM ASSAYS Trofile® and Trofile® DNA provide critical information for informed treatment decisions HIV-1 can attach to human cells either by using the CCR5 coreceptor, the CXCR4 coreceptor, or both (dual/mixed). Tropism testing determines how the virus can attach to the cells in a given patient. Possible tropism results are R5, DM, X4, and X4 near the limit of detection (NLOD). Why does my patient’s tropism matter? Trofile® DNA HIV tropism results can help you develop a personalized Applies the proven performance of Trofile to cell-associated treatment plan for your patient. Appropriate use of CCR5 viral DNA antagonists including maraviroc requires that an HIV tropism Consider Trofile® DNA when a patient’s viral load is test be performed before initiation of therapy.1 undetectable, tropism is unknown, and substitution with a CCR5 antagonist-containing regimen is desired. Regimen substitution may be considered when2 Trofile® • Laboratory results or clinical adverse events necessitate A highly sensitive assay that provides critical information when a change7,8 selecting a treatment regimen containing maraviroc • Patient exhibits intolerance to the current regimen7 • Trofile was utilized to identify treatment candidates in the • There is concern regarding the long-term effects of the maraviroc multicenter clinical trials.1 current regimen8 • Both the current DHHS and IDSA guidelines recommend tropism testing before initiation of treatment with a CCR5 antagonist.2,3 GenoSure Archive® Plus Trofile® DNA • Trofile is the only commercially available tropism assay Comprehensive suppression management profile that has been clinically validated through use in Phase 2 Designed to provide a comprehensive assessment of and Phase 3 clinical studies to identify CCR5 five antiretroviral drug classes (GenoSure Archive: NRTIs, antagonist candidates.4-6 NNRTIs, PIs, INIs and Trofile DNA: CCR5 antagonist) to facilitate regimen simplification or switches in the setting of Virologic suppression.
    [Show full text]
  • Leo's Lulu MASTER
    TOM SWIFT and the Cometary Reclamation BY Leo L. Levesque & Thomas Hudson Book two in the trilogy that began with Tom Swift and His Space Battering Ram A Joint Levesque Publishing Empire / Thackery Fox & Assoc. Publication Made in The United States on America ©opyright 2014 by the authors of this book (Leo L. Levesque and Thomas Hudson). While some of the characters in this story have appeared in other books and collections of books, published by other entities, it is believed that all have fallen into Public Domain status. Fair use under U.S. Copyright Law provisions for “parodies” is claimed for their inclusion in this story. The book authors retain all ownership and copyrights to new or substantially altered characters, previously unpublished locations and situations, and to their contributions to this book and to the total story. The characters Damon Swift, Anne Swift and Bashalli Prandit were created by Scott Dickerson and are used through his incredible largess and understanding that they are superior to those they replaced. This book is a work of fan fiction. It is not claimed to be part of any previously published adventures of the main characters. It has been self-published and is not intended to supplant any authored works attributed to the pseudononomous author, Victor Appleton II, or to claim the rights from any legitimate publishing entity. 2 Tom Swift and the Cometary Reclaimation By Leo L. Levesque and Thomas Hudson After Tom saves the world from the rouge comet meant to wreck havoc on the Earth, the Swifts work along with Harlan Ames, recently elevated to head of the former Master’s lunar colony, to see what the situation might now be.
    [Show full text]
  • Relative Influence of Dietary Protein and Energy Contents on Lysine
    British Journal of Nutrition, page 1 of 15 doi:10.1017/S0007114517003300 © The Authors 2017 Relative influence of dietary protein and energy contents on lysine requirements and voluntary feed intake of rainbow trout fry Mélusine Van Larebeke*, Guillaume Dockx, Yvan Larondelle and Xavier Rollin* Institut des Sciences de la Vie, Université catholique de Louvain, Place Croix du Sud 2/L7.05.08, 1348 Louvain-la-Neuve, Belgium (Submitted 7 January 2017 – Final revision received 29 October 2017 – Accepted 30 October 2017) Abstract The effect of dietary digestible protein (DP) and/or digestible energy (DE) levels on lysine (Lys) requirements, Lys utilisation efficiency and voluntary feed intake (VFI) were studied in rainbow trout fry when Lys was the first limiting indispensable amino acid or in excess in the diet. Two trials were conducted at 11·6°C with eighty-one experimental diets, containing 280 g DP/kg DM (low protein (LP), trial 1), 600 g DP/kg DM (high protein (HP), trial 1) or 440 g DP/kg DM (medium protein (MP), trial 2), 17 MJ DE/kg (low energy (LE)), 19·5 MJ DE/kg (medium energy (ME)) or 22 MJ DE/kg (high energy (HE)), and nine Lys levels from deeply deficient to large excess (2·3–36 g/kg DM). Each diet was given to apparent satiety to one group of fifty fry (initial body weight 0·85 g) for 24 (MP diets, trial 2) or 30 (LP and HP diets, trial 1) feeding days. Based on N gain data fitted with the broken-line model, the relative Lys requirement was significantly different with the dietary DP level, from 13·3–15·7to22·9–26·5 g/kg DM for LP and HP diets, respectively, but did not significantly change with the DE level for a same protein level.
    [Show full text]
  • Determination of HIV-1 Coreceptor Tropism Using Proviral DNA In
    Baumann et al. AIDS Research and Therapy (2015) 12:11 DOI 10.1186/s12981-015-0055-x RESEARCH Open Access Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression Russell E Baumann1, Amy A Rogers1, Hasnah B Hamdan1, Harold Burger2, Barbara Weiser2, Wei Gao3, Kathryn Anastos3, Mary Young4, William A Meyer III5, Rick L Pesano1 and Ron M Kagan1* Abstract Background: An HIV-1 tropism test is recommended prior to CCR5 antagonist administration to exclude patients harboring non-R5 virus from treatment with this class of antiretrovirals. HIV-1 tropism determination based on proviral DNA (pvDNA) may be useful in individuals with plasma viral RNA suppression. We developed a genotypic tropism assay for pvDNA and assessed its performance in a retrospective analysis of samples collected longitudinally. Results: We randomly selected paired plasma/PBMC samples from the Women’s Interagency HIV Study with plasma viral load ≥5,000 cp/mL at time 1 (T1), undetectable viral load maintained for ≥1 year and CD4+ >200 cells/μLattime 2 (T2). pvDNA was isolated from cryopreserved PBMCs. Sequences were analyzed in triplicate from 49/50 women, with tropism assigned using the geno2pheno (g2p) algorithm. The median time between T1 and T2 was 4.1 years. CXCR4-using virus was detected in 24% of the RNA samples and 33% of the pvDNA samples at T1, compared to 37% of the pvDNA samples at T2. Concordance between plasma RNA and pvDNA tropism was 88% at T1 and 80% at T2. The g2p scores for RNA (T1) vs DNA (T1, T2) were strongly correlated (Spearman rho: 0.85 (T1); 0.78 (T2)).
    [Show full text]
  • CCHCS Care Guide: Human Immunodeficiency Virus (HIV)
    September 2021 CCHCS Care Guide: Human Immunodeficiency Virus (HIV) SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT ALL HIV INFECTED PATIENTS MUST BE MANAGED BY A CCHCS HIV SPECIALIST GOALS • Offer HIV screening to all • Ensure a sexual history and appropriate risk reduction counseling is performed • Refer all patients with HIV to HIV specialists as by a primary care team member for every patient with HIV at least annually. soon as possible • Initiate antiretroviral therapy (ART) for all patients with HIV as soon as possible • Identify newly diagnosed cases of HIV/Acquired • Screen and evaluate the patients with substance use disorder as a Immunodeficiency Syndrome (AIDS) transmission risk factor (see CCHCS Substance Use Disorder Care Guide) • Identify acute HIV seroconversion ALERTS Inappropriate or suboptimal treatment regimens Red Flags • Patients receiving only one HIV medication rather than a multi-drug ANY CD4 CD4 <200 CD4 <100 combination (note that some co-formulations exist) • New onset fevers • Dyspnea • Headache • Patients on treatment for months with a persistently detectable viral • Weight loss >10% • Cough • Blurry or lost load • Fatigue • Fevers vision • Patients with CD4 <200 cells/mm3 who are not on Pneumocystis • Skin lesions • Diarrhea jiroveci (PCP) prophylaxis (see page 6) • Night sweats DIAGNOSTIC CRITERIA/EVALUATION (SEE PAGE 2 FOR HIV TESTING ALGORITHM) D Consider HIV in the following circumstances: • Patients with known high risk behaviors prior to or during incarceration (tattoos, injection drug use,
    [Show full text]
  • A Genotypic HIV-1 Proviral DNA Coreceptor Tropism Assay: Characterization in Viremic Subjects
    UC Davis UC Davis Previously Published Works Title A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects. Permalink https://escholarship.org/uc/item/48m71302 Journal AIDS research and therapy, 11(1) ISSN 1742-6405 Authors Brown, Jennifer Burger, Harold Weiser, Barbara et al. Publication Date 2014 DOI 10.1186/1742-6405-11-14 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Brown et al. AIDS Research and Therapy 2014, 11:14 http://www.aidsrestherapy.com/content/11/1/14 METHODOLOGY Open Access A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects Jennifer Brown1*, Harold Burger2, Barbara Weiser2, Richard B Pollard1, Xiao-Dong Li2, Lynell J Clancy1, Russell E Baumann3, Amy A Rogers3, Hasnah B Hamdan3, Rick L Pesano3 and Ron M Kagan3 Abstract Background: HIV-1 coreceptor tropism testing is used to evaluate eligibility for CCR5 antagonist therapy. However, HIV-1 RNA-based tests are not suitable for virologically suppressed patients, therefore the use of proviral DNA tropism testing has been investigated. We describe a novel proviral DNA-based genotypic tropism assay and compare its performance to that of a sensitive HIV-1 RNA-based genotypic test. Methods: Tropism was determined using HIV-1 plasma RNA and proviral DNA from 42 paired samples from patients with plasma viral loads ≥1000 HIV-1 RNA copies/mL. Proviral DNA sample types included whole blood, separated peripheral blood mononuclear cells resuspended in phosphate-buffered saline and peripheral blood mononuclear cells resuspended in spun plasma. The HIV-1 envelope V3 region was PCR-amplified, sequenced in triplicate, and analyzed for tropism with the geno2pheno algorithm using a 10% false-positive rate (FPR).
    [Show full text]
  • IAS 2007, Sydney Australia
    Pa m a g oa z i n e sf o r pie o tp l e il i vvi n g wei t h h iLv / a i d s i! ovc t o b ie r 2n0 0 7 g IAS 2007, Sydney Australia PROMISING SIGNS, MORE COMMUNITY INVOLVEMENT, NEW TREATMENTS BY PAUL KIDD the partnership was threatened by want to help people, not judge recent political developments. them.” major HIV/AIDS “Recent comments by high Maura Mea, an HIV- medical conference in governmental authorities have cast positive woman from Papua Sydney has generated doubt on Australia’s commitment New Guinea, reminded the lots of news on the to reduce stigma and discrimination audience of the importance of treatments front. for people living with HIV,” said maintaining a strong Several of the big guns IAS president Pedro Cahn. involvement by people living of recent HIV drug “Fortunately, neither the scientific with HIV/AIDS in the development have community nor the Australian response to the epidemic, in continuedA to perform well in clinical people support these statements. our region and globally. trials, and there are promising signs in We stand united with local and “One of the keys to dealing with toxicities, neurological global AIDS community to ensure addressing the HIV epidemic is complications and more. that people living with HIV have to address stigma and The International AIDS Society the right to travel without discrimination,” she said. “An conference on HIV Pathogenesis, harassment or the requirement to important way of doing this is Treatment and Prevention is held disclose their HIV status.” to put a real human face to every second year.
    [Show full text]
  • Agriculture, Climate Change and Food Security in the 21St Century
    Agriculture, Climate Change and Food Security in the 21st Century Agriculture, Climate Change and Food Security in the 21st Century: Our Daily Bread By Lewis H. Ziska Agriculture, Climate Change and Food Security in the 21st Century: Our Daily Bread By Lewis H. Ziska This book first published 2017 Cambridge Scholars Publishing Lady Stephenson Library, Newcastle upon Tyne, NE6 2PA, UK British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library Copyright © 2017 by Lewis H. Ziska All rights for this book reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner. ISBN (10): 1-5275-0314-3 ISBN (13): 978-1-5275-0314-4 To the Librarians of Bangor, Maine The True Guardians of the Galaxy And Leneida M. Crawford My Guardian TABLE OF CONTENTS Preface ......................................................................................................... x Part I. Setting the Table Chapter One ................................................................................................. 2 Breakfast of Champions Chapter Two ................................................................................................ 8 Hunger is No Game Chapter Three ............................................................................................ 12 A Brief History of Agriculture, Civilization and Famine Part II.
    [Show full text]
  • WO 2014/043009 Al 20 March 2014 (20.03.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2014/043009 Al 20 March 2014 (20.03.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 8/64 (2006.01) A61K 8/99 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 8/65 (2006.01) A61Q 19/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/US20 13/058693 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, >September 2013 (09.09.2013) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English 4 Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/701,130 14 September 2012 (14.09.2012) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: ELC MANAGEMENT LLC [US/US]; Suite TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 345 South, 155 Pinelawn Road, Melville, NY 11747 (US).
    [Show full text]